Efficacy of GONB in Patients of Migraine

Analgesic Efficacy of Ultrasound-guided Greater Occipital Nerve Block in Patients of Chronic Migraine

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05679765

Enrollment

Registered

2023-01-11

Start date

2022-04-01

Completion date

2022-08-31

Last updated

2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine, Headache

Brief summary

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Interventions

DRUGGreater Occipital Nerve Block with dexamethasone and lidocaine

Ultrasound guided Greater occipital nerve block on the side of headache

DRUGGreater Occipital Nerve Block with 0.9% saline

Ultrasound guided Greater occipital nerve block on the side of headache

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients between 18 to 60 years * diagnosed case of migraine

Exclusion criteria

* Patients with known allergies to local anaesthetics * pregnancy * history of cranial or cervical surgery * head injury * headaches secondary to medication overuse * patients with uncontrolled systemic disease like blood pressure, diabetes mellitus * hypo or hyperthyroidism * patient who had already received GONB or botulinum toxin type A therapy within last 6 months * major psychiatric disorder * history of chronic pain syndromes

Design outcomes

Primary

Measure	Time frame	Description
Analgesic efficacy	12 weeks	Change in Pain score assessed on Numeric Rating Scale (NRS) which ranges from 0 to 10. 0 is no pain and 10 is maximum pain.

Secondary

Measure	Time frame	Description
Headache days	12 weeks	Number of headache days over the course of study period.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026